Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-04-17

FDA Approved: TROGARZO — Supplemental Application (Theratechnologies Inc.)

View source ↗

Summary

The FDA approved a supplemental Biologics License Application for TROGARZO (ibalizumab) from Theratechnologies Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trogarzo (ibalizumab)

Snippet

SUPPL AP for TROGARZO (IBALIZUMAB)